Don't Recommend Spiriva First-Line for Mild COPD

New evidence will spark controversy over how to treat COPD patients with MILD disease.

About seven in 10 COPD patients have early disease with minimal symptoms. But meds are usually studied in moderate to severe COPD.

Now evidence suggests that Spiriva (tiotropium), a long-acting muscarinic antagonist (LAMA), may be beneficial for mild COPD.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote